What’s been happening under cover with prescribing is now out in the open, says Noel Wicks
It seems that NHS England is taking a leaf out of the book of certain CCGs with its recent announcement to review a selection of “low value” medicines that it believes may have limited clinical value. The 10 items include tadalafil, travel vaccines, lidocaine plasters, fentanyl and doxazosin. In total, this could yield about £130 million in savings, although I imagine this assumes that no alternatives are prescribed.
This seems a far cry from the £400 million that Simon Stevens suggested could be saved by this review. So where is the rest coming from? Alongside this initial list of specified medicines NHS England also intends review other areas such as gluten-free foods and minor ailments including hayfever, pain and indigestion.